4CPS-270 Results of effectiveness and safety in real clinical practice of nivolumab, pembrolizumab and atezolizumab in non-small cell lung cancer

Abstract

Conclusion and relevance Considering the positive results obtained so far, the study of HIPEC with CRS in peritoneal carcinoma continues, to evaluate its effectiveness. The role of the pharmacist was important in participating in the multidisciplinary team in terms of eligibility of patients for treatment, to prepare oncological therapies and in processing the evaluation data.